Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNYSEAMERICAN:AZTRNASDAQ:EDSANASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.21-7.8%$0.30$0.15▼$13.00$11.07M-0.015.71 million shs2.58 million shsAZTRAzitra$0.29+0.6%$0.30$0.23▼$12.00$3.58M-1.332.81 million shs140,878 shsEDSAEdesa Biotech$1.96-2.5%$2.28$1.55▼$5.59$14.12M0.55490,386 shs12,991 shsMBRXMoleculin Biotech$0.95+1.2%$0.96$0.40▼$5.12$13.44M1.641.47 million shs103,698 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-7.83%-7.83%-34.61%-74.67%+21,199,900.00%AZTRAzitra+0.60%+6.22%-2.75%-22.06%-94.75%EDSAEdesa Biotech-2.49%-3.45%-17.26%-17.65%-57.11%MBRXMoleculin Biotech+1.20%+1.17%-7.67%-25.70%-80.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AAZTRAzitra0.7322 of 5 stars0.02.00.00.03.30.01.3EDSAEdesa Biotech2.6014 of 5 stars3.55.00.00.00.91.70.6MBRXMoleculin Biotech2.1794 of 5 stars3.52.00.00.02.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,786.79% UpsideAZTRAzitra 0.00N/AN/AN/AEDSAEdesa Biotech 3.00Buy$21.00971.43% UpsideMBRXMoleculin Biotech 3.00Buy$6.00530.91% UpsideCurrent Analyst Ratings BreakdownLatest AZTR, ABP, EDSA, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.003/24/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/13/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/3/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/24/2025ABPAbproMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K60.49N/AN/AN/A∞AZTRAzitra$690K5.19N/AN/A$7.23 per share0.04EDSAEdesa BiotechN/AN/AN/AN/A$0.18 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbproN/AN/A0.00∞N/AN/AN/AN/AN/AAZTRAzitra-$11.28MN/A0.00N/AN/AN/A-212.16%-145.36%8/11/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-233.69%-124.14%8/8/2025 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/12/2025 (Estimated)Latest AZTR, ABP, EDSA, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AAZTRAzitraN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/AN/AN/AAZTRAzitraN/A5.585.58EDSAEdesa BiotechN/A1.090.91MBRXMoleculin BiotechN/A2.082.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%AZTRAzitra11.16%EDSAEdesa Biotech5.50%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%AZTRAzitra0.56%EDSAEdesa Biotech22.60%MBRXMoleculin Biotech1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1552.22 million4.57 millionN/AAZTRAzitra1012.48 million12.41 millionNot OptionableEDSAEdesa Biotech207.02 million2.60 millionNot OptionableMBRXMoleculin Biotech2014.13 million3.86 millionNot OptionableAZTR, ABP, EDSA, and MBRX HeadlinesRecent News About These CompaniesRoth Capital Has Positive Estimate for MBRX Q2 EarningsMay 18, 2025 | americanbankingnews.comEarnings call transcript: Moleculin Biotech reports Q1 2025 updatesMay 15, 2025 | uk.investing.comMOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly EarningsMay 15, 2025 | nasdaq.comMoleculin Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical TrialMay 12, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Expands Phase 3 Trial of Annamycin for R/R AML to Nine EU Countries, Enrollment UnderwayMay 12, 2025 | quiverquant.comMoleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical TrialMay 12, 2025 | globenewswire.comMoleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and WebcastMay 7, 2025 | globenewswire.comMoleculin secures two new US patents for cancer drug AnnamycinMay 6, 2025 | investing.comMoleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML TreatmentMay 6, 2025 | quiverquant.comMoleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for AnnamycinMay 6, 2025 | globenewswire.comMoleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. PatentsMay 5, 2025 | globenewswire.comMoleculin reports Annamycin cancer drug synergy at AACR meetingApril 30, 2025 | investing.comMoleculin Biotech Presents Promising Annamycin Data at AACR Annual Meeting 2025, Highlighting Synergistic Potential with FDA Approved Cancer TherapiesApril 30, 2025 | nasdaq.comMoleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic CancerApril 29, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation OnlineApril 21, 2025 | tipranks.comMoleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025April 17, 2025 | globenewswire.comMoleculin Biotech begins dosing subjects in combination therapy trial for AMLApril 2, 2025 | clinicaltrialsarena.comMoleculin Biotech doses first patient in Phase 3 MIRACLE trialApril 2, 2025 | finance.yahoo.comHere's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock NowApril 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZTR, ABP, EDSA, and MBRX Company DescriptionsAbpro NASDAQ:ABP$0.21 -0.02 (-7.83%) As of 05/23/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Azitra NYSEAMERICAN:AZTR$0.29 +0.00 (+0.60%) Closing price 05/23/2025 04:10 PM EasternExtended Trading$0.28 -0.01 (-2.06%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Edesa Biotech NASDAQ:EDSA$1.96 -0.05 (-2.49%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.99 +0.03 (+1.53%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Moleculin Biotech NASDAQ:MBRX$0.95 +0.01 (+1.20%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.93 -0.02 (-2.21%) As of 05/23/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
